膀胱肿瘤电切术后辅以膀胱内灌注抗肿瘤药物是治疗浅表性膀胱癌的金标准，然而目前临床上膀胱灌注效率低下，是造成膀胱癌治疗后易复发的重要原因之一。很多研究尝试新型材料作为药物载体来提高膀胱灌注的效率，但仍有很多不足，主要集中在：药物载体的肿瘤靶向性、药物载体的穿透性及载体释放药物的可控性等方面。针对目前膀胱灌注中存在缺陷以及研究中的不足，申请人拟在前期工作基础上利用泊洛沙姆温敏漂浮凝胶，树枝状高分子材料PAMAM，肿瘤靶向多肽RGD，构建一种肿瘤靶向性好、穿透性强并可控释放的复合载药系统。本研究利用该复合载药系统同时装载抗肿瘤药物阿霉素及肿瘤干细胞抑制剂盐霉素，着重评估该载药系统在增加膀胱灌注效率及减轻副作用方面的效果，希望为浅表型膀胱癌治疗后易复发这一临床难题开拓有效并可行的解决手段，也为建立我国自主知识产权的膀胱灌注给药系统提供思路。

Intravesical instillation of anti-tumor agents post resection of bladder cancer is the golden standard for the treatment of superficial bladder cancer. However, the efficacy of intravesical instillation is low, leading to the high recurrence rate after treatment. Recently, many researches have been conducted attempting to improve the efficacy of intravesical instillation by using drug delivery system. However, several issues are needed to be resolved including tumor targeting, high penetration, and controlled release of the designed delivery system. In the present project, we attempt to establish a complex drug delivery system based on poloxamer, a thermo-sensitive hydrogel, PAMAM, a dendrimer polymer material, and RGD, a tumor-targeting peptide. Doxorubicin, a common anti-tumor agent and salinomycin, a specific inhibitor of cancer stem cells are both loaded in this system. The effect of the designed drug delivery system in improving the efficacy of intravesical instillation and reducing side effects will be evaluated. We intend to provide an effective and feasible strategy for the treatment of superficial bladder cancer. In addition, we intend to provide new perspective for the development of drug delivery system for intravesical instillation with intellectual property right.